Introduction {#s1}
============

The number of patients with type 2 diabetes has increased worldwide. Because patients with type 2 diabetes often have dyslipidemia, it is important to normalize their lipid levels in order to prevent cardiovascular diseases \[[@R01]-[@R03]\].

Postprandial glucose excursion is correlated with an increase in cardiovascular dysfunction \[[@R04], [@R05]\]. Dipeptidyl peptidase-4 (DPP-4) inhibitors and alpha-glucosidase inhibitors (α-GIs) are effective in reducing the postprandial glucose levels. Seven types of DPP-4 inhibitors, that are taken daily, are available in Japan.

Takihata et al reported that the administration of sitagliptin, but not pioglitazone, decreased low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in Japanese patients with type 2 diabetes \[[@R06]\]. Chiba et al also reported that anagliptin significantly reduced total cholesterol (TC) (i.e. LDL-C and HDL-C levels) in patients with type 2 diabetes \[[@R07]\]. Of note, a meta-analysis of DPP-4 inhibitors suggested that treatment with DPP-4 inhibitors was also associated with a significant reduction in TC \[[@R08]\]. Recently, we reported that lathosterol, a cholesterol synthesis marker, was suppressed after 1 month of treatment with anagliptin, a DPP-4 inhibitor \[[@R9]\]. However, this investigation was observational, and the duration of treatment was short. Therefore, in this study, we administered either anagliptin or miglitol, which are α-GIs, for 3 months in patients with type 2 diabetes and compared lipid-lowering effects of anagliptin with those of miglitol.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

This study was approved by the Institutional Ethics Review Committee of Yokohama City University Hospital, and the protocol was registered in the University Hospital Medical Information Network (UMIN) Clinical Trial Registry as UMIN000021494. Written informed consent was obtained from each of the patients before the start of the study.

As the desired target for the primary prevention of ischemic heart diseases in Japanese patients with type 2 diabetes was LDL-C level of \< 120 mg/dL, we enrolled male and female patients aged 20 - 75 years with type 2 diabetes LDL-C level of 120 mg/dL and over and without any prior treatment with DPP-4 inhibitors, α-GIs and cholesterol-lowering drugs. Patients were prohibited from receiving another anti-diabetic drug during the study.

Study design {#s2b}
------------

The study was an open-label, randomized, parallel-group clinical trial. Patients were recruited from March 2016 to November 2018 and randomly assigned (1:1) to either the anagliptin group or the miglitol group ([Fig. 1](#F1){ref-type="fig"}). Patients who were assigned to the anagliptin group took 100 mg tablets twice a day before breakfast and dinner, and patients who were assigned to the miglitol group took 50 mg tablet three times a day before every meal. Patients were asked to visit the hospital at 0, 4 ± 1, and 12 ± 2 weeks.

![Schematic presentation of this study.](jocmr-12-073-g001){#F1}

We instructed the patients not to change their daily routine including their food intake and exercise habits for 12 weeks. Patients were asked every day whether they have taken the medicine and were asked to write any side effects in a diary. The results of laboratory data before and after treatment were explained to the patients only after the end of intervention to prevent any changes in diet or exercise based on the knowledge of the laboratory results. A meal tolerance test was conducted before the treatment and 12 weeks after the treatment. All the subjects received a standard breakfast (773 kcal; protein: 27.0 g; fat: 20.3 g; carbohydrate: 121.5 g). For the study, the subjects were requested to fast for at least 12 h. Blood samples were collected at 0, 60, and 120 min after breakfast. Blood test was also conducted at 4 weeks after the treatment to check adverse effects of drugs.

Endpoints {#s2c}
---------

The primary end-point was a difference in LDL-C at 12 weeks between the anagliptin group and the miglitol group. The secondary end-points were differences in TC, HDL-C, non-HDL-C, triglyceride (TG), lathosterol, sitosterol, campesterol, cholestanol, malondialdehyde-modified LDL-C (MDA-LDL-C), small dense LDL-C (sd-LDL-C), apolipoprotein B-48 (apoB-48), apoB-100 and hemoglobin A1c (HbA1c) at 12 weeks between the two groups. Lathosterol, sitosterol, campesterol, cholestanol and apoB-48 were measured at SRL Co. (Tokyo, Japan). Cholesterol synthesis and absorption markers were measured using gas chromatography. ApoB-100 was measured using an ELISA kit (Millipore Corp, MA, USA) in our laboratory. Remaining factors were measured in the clinical laboratory of Yokohama City University Hospital.

Statistical analysis {#s2d}
--------------------

Similar to our previous study on lipid-lowering effects of anagliptin in 30 outpatients with type 2 diabetes \[[@R10]\], the sample size in each group in this study also included 30 patients (total 60 patients). All statistical factors were decided prior to the study and all the statistical analyses were conducted and monitored by EMI Inc. (Osaka, Japan). Data were expressed as mean ± standard deviation (SD). Sex ratio/distribution was compared by χ^2^ test and age. Duration of diabetes and the percentage of patients who did not take any medicine were analyzed by Student's *t*-test. Data between baseline and week 4 in each group were compared by paired *t*-test. Data from the anagliptin group and miglitol group were compared at 12 weeks using a linear mixed model. Differences were considered significant at P \< 0.05.

Results {#s3}
=======

Baseline clinical characteristics {#s3a}
---------------------------------

[Table 1](#T1){ref-type="table"} shows the baseline characteristics of patients. Out of 52 patients, 29 patients were assigned to the anagliptin group and 23 patients to the miglitol group, and 27 and 20 of these patients completed the study, respectively. There were no statistically significant differences between the groups with respect to baseline patient characteristics, including the age, sex and the duration of diabetes.

###### Patient Characteristics

                                       Anagliptin group (n = 29)   Miglitol group (n = 23)   P
  ------------------------------------ --------------------------- ------------------------- --------
  Sex ratio/distribution (men/women)   23/6                        19/4                      1.0000
  Age (years)                          53.7 ± 8.5                  56.3 ± 8.4                0.2865
  Duration of diabetes (years)         6.5 ± 7.9                   3.6 ± 3.2                 0.0789
  Body weight (kg)                     77.0 ± 17.1                 75.6 ± 13.7               
  Height (cm)                          165.6 ± 7.0                 167.8 ± 8.1               
  Body mass index (kg/m^2^)            27.9 ± 4.6                  26.8 ± 4.3                

Changes in serum lipid profiles {#s3b}
-------------------------------

In the anagliptin group, HbA1c, HDL-C, and non HDL-C were decreased significantly during the 12-week treatment. However, no significant change was observed in lathosterol, campesterol, sitosterol, and cholestanol. In the anagliptin group, TC was increased by the treatment but the difference was not statistically significant (P = 0.0929). In the miglitol group, HbA1c, campesterol and sitosterol decreased significantly by the end of the 12-week treatment. This group also showed an increase in lathosterol. However, this value is not statistically significant (P = 0.0599). In conclusion, no significant differences in HbA1c, LDL-C, TC, HDL-C, TG, lathosterol, campesterol, sitosterol, cholestanol, apoB-48, apoB-100, sd-LDL, and MDA-LDL were observed between the anagliptin group and miglitol group ([Table 2](#T2){ref-type="table"}).

###### Comparison of Parameters Before and After Treatment With Anagliptin or Miglitol

                        Anagliptin group (n = 29)   Miglitol group (n = 23)   P3                                                                            
  --------------------- --------------------------- ------------------------- -------------- -------- -------------- -------------- -------------- -------- --------
  Number                29                                                    27                      23                            20                      
  HbA1c (%)             7.9 ± 1.2                   7.6 ± 1.3                 7.2 ± 1.3      0.0000   8.0 ± 1.8      7.4 ± 1.3      7.3 ± 1.1      0.0068   0.0773
  LDL-C (mg/dL)         153.8 ± 30.7                149.7 ± 24.5              147.6 ± 23.1   0.1897   148.1 ± 22.8   140.7 ± 19.6   150.3 ± 20.3   0.2114   0.1717
  HDL-C (mg/dL)         53.4 ± 15.7                 52.4 ± 16.0               51.8 ± 15.7    0.0216   59.0 ± 11.4    55.5 ± 12.7    55.9 ± 13.5    0.1821   0.7419
  Non HDL-C (mg/dL)     176.8 ± 35.4                171.1 ± 27.2              169.6 ± 25.1   0.0165   170.0 ± 25.5   159.2 ± 20.5   170.5 ± 22.2   0.5668   0.2869
  TC (mg/dL)            230.2 ± 40.0                223.6 ± 30.1              221.4 ± 31.2   0.0929   229.0 ± 29.3   214.8 ± 26.4   226.4 ± 28.1   0.9349   0.1899
  TG (mg/dL)            154.2 ± 92.4                146.4 ± 78.5              152.0 ± 72.1   0.8439   153.6 ± 63.0   140.7 ± 46.4   145.0 ± 59.9   0.3754   0.4892
  ApoB-48 (µg/mL)       3.8 ± 4.1                   \-                        4.2 ± 3.4      0.3900   5.0 ± 7.1      \-             5.1 ± 4.5      0.9585   0.7369
  ApoB-100 (µg/mL)      4.3 ± 1.1                   \-                        4.3 ± 1.1      0.6403   4.4 ± 1.0      \-             4.2 ± 0.9      0.2579   0.5828
  Sd-LDL-C (mg/dL)      56.6 ± 21.9                 \-                        49.2 ± 14.8    0.0510   55.6 ± 18.0    \-             53.5 ± 18.7    0.4529   0.2632
  MDA-LDL-C (U/L)       164.1 ± 38.6                \-                        152.3 ± 34.7   0.1046   166.2 ± 41.2   \-             173.3 ± 82.3   0.5829   0.1075
  Lathosterol (µg/mL)   3.2 ± 1.3                   \-                        3.1 ± 1.2      0.7182   3.4 ± 1.2      \-             3.1 ± 1.3      0.0599   0.4334
  Campesterol (µg/mL)   4.1 ± 1.7                   \-                        4.5 ± 1.9      0.2177   4.1 ± 2.1      \-             4.4 ± 2.6      0.0407   0.4254
  Sitosterol (µg/mL)    2.2 ± 0.9                   \-                        2.4 ± 1.0      0.1365   2.1 ± 1.0      \-             2.4 ± 1.3      0.0441   0.3156
  Cholestanol (µg/mL)   2.5 ± 0.8                   \-                        2.5 ± 0.8      0.6713   2.4 ± 0.5      \-             2.5 ± 0.6      0.1513   0.7512

P1: comparison of changes between baseline and after 12 weeks in anagliptin group; P2: comparison of changes between baseline and after 12 weeks in miglitol group; and P3: comparison of each level between anagliptin group and miglitol group at 12 weeks. HbA1c: hemoglobin A1c; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; apoB-48: apolipoprotein B-48; apoB-100: apolipoprotein B-100; MDA-LDL-C: malondialdehyde-modified LDL-C; sd-LDL-C: small dense LDL-C.

Regarding the meal tolerance test, TG and apoB-48 levels decreased at 60 min in the miglitol group, but there were no significant changes in TG and apoB-48 after 12 weeks of treatment with anagliptin or miglitol ([Fig. 2](#F2){ref-type="fig"}).

![Serum triglyceride and apolipoprotein B-48 levels by meal tolerance test before and after treatment. (a) Changes in triglyceride, and (b) changes in apolipoprotein B-48. \# P \< 0.05; \#\# P \< 0.01 compared with baseline (0 week).](jocmr-12-073-g002){#F2}

Adverse effects {#s3c}
---------------

Adverse effects are described in [Table 3](#T3){ref-type="table"}. Gastrointestinal symptoms were observed in the anagliptin (three patients, 11.1%) and miglitol groups (15 patients, 75.0%), respectively. None of them discontinued. One case of drug eruption was observed in the anagliptin group and two cases of serious weight loss were observed in the miglitol group. Both patients were not given more medicine. No severe cases of hypoglycemia were observed in either group during the trial. As shown in [Table 4](#T4){ref-type="table"}, there was no significant difference in the rate of forgetfulness about taking the drugs between the two groups (1.6±3.5% vs. 3.4±4.6%, P = 0.1184).

###### Adverse Effects

  Adverse effects             Anagliptin group   Miglitol group
  --------------------------- ------------------ ----------------
  Gastrointestinal symptoms   3                  15
  Drug eruption               1                  
  Liver dysfunction           1                  
  Weight loss                                    2

Values are n.

###### Medication Adherence

  Medication adherence                            Anagliptin group   Miglitol group   P
  ----------------------------------------------- ------------------ ---------------- --------
  Percentage forgetting to take oral medication   1.58 ± 3.46        3.36 ± 4.59      0.1184

Discussion {#s4}
==========

The most important finding of this study was that there was no significant difference in LDL-C, cholesterol synthesis, and absorption marker between the anagliptin and miglitol groups. In the anagliptin group, HDL-C, non HDL-C were decreased significantly by 3-month treatment. In contrast, in the miglitol group, while non HDL-C was not decreased significantly, campesterol and sitosterol were increased significantly by 3-month treatment, and lathosterol tends to decrease by this treatment, although statistically, the difference is not significant.

DPP-4 inhibitors have been reported to decrease LDL-C and TC levels \[[@R06]-[@R08]\]. It was reported that anagliptin was superior to sitagliptin in lowering LDL-C in the patients with type 2 diabetes in a randomized clinical trial \[[@R10]\]. We here evaluated the lipid-lowering effects of anagliptin in Japanese patients with type 2 diabetes in randomized clinical trial by comparing it with miglitol, which improved postprandial plasma glucose similarly. Previously, we administered anagliptin in patients with type 2 diabetes, whose LDL-C levels were over 120 mg/dL, and who were not on any medications \[[@R9]\]. After 1 month, lathosterol was decreased significantly by anagliptin treatment. In this study, we could not observe a significant decrease in lathosterol, and this may be due to the differences in baseline LDL-C, number of subjects, duration of treatment, and/or weak lipid-lowering effect of anagliptin.

Several reports have indicated that cholesterol metabolism can be improved through DPP-4 inhibitors in animal models. Vildagliptin decreased expressions of the genes involved in hepatic cholesterol biosynthesis, such as phosphomevalonate kinase (PMVK), acyl-coenzyme A dehydrogenase medium chain (ACADM), diphosphomevalonate decarboxylase (MVD), and acyl-CoA synthetase (ACSL1) \[[@R11]\]. Yano et al reported that sterol regulatory element-binding protein-2 (SREBP2) mRNA expression level was significantly decreased at night with anagliptin treatment in LDL receptor-deficient mice \[[@R12]\]. These results suggest the down-regulation of lipid synthesis by liver. Anagliptin significantly suppressed SREBP activity in HepG2 cells. Goto et al also reported that anagliptin improved hypercholesterolemia in apoE-deficient mice by inhibiting intestinal cholesterol transport \[[@R13]\]. Thus, in animal model studies, DPP-4 inhibitor decreases cholesterol synthesis and absorption. However, the lipid-lowering effect of DPP-4 inhibitors, including anagliptin, is small compared with statins in humans. Therefore, it is difficult to investigate the mechanisms of anagliptin-induced alterations in lipid metabolism by checking cholesterol synthesis and absorption markers.

Regarding the effect of miglitol on lipid metabolism, it was reported that miglitol treatment decreased LDL-C in subjects with metabolic syndrome \[[@R14]\]. In our study, LDL-C levels were not decreased significantly. Fecal concentration of campesterol was reported to be decreased by acarbose in healthy subjects \[[@R15]\]. This result suggests that α-GI increases absorption of campesterol and may be consistent with our results, which indicates that miglitol treatment leads to lowered campesterol levels. Thus, lathosterol was decreased for compensation. Further investigation is needed for this effect.

We previously investigated the improvement of drug adherence in patients who had taken miglitol \[[@R16]\]. While miglitol is administered to patients three times a day, anagliptin is administered twice a day in this study. As shown in [Table 4](#T4){ref-type="table"}, there was no significant difference of drug adherence between anagliptin and miglitol groups, but this may be due to the small sample size. It was previously published that increased number of drug intake worsens the drug adherence \[[@R17]\]. Regarding drug adherence and effect on lipids, anagliptin will be administered to patients with postprandial hyperglycemia and high non HDL-C levels, rather than miglitol.

Chiba et al reported that anagliptin treatment decreased LDL-C more in cases with initial high level of LDL-C (\> 120) than in those with an initial low level of LDL-C (\< 120) \[[@R07]\]. Therefore, we will investigate lipid-lowering effect of anagliptin according to the baseline LDL-C along with cholesterol synthesis and absorption markers in the *post hoc* analysis.

The present study had several limitations. We included patients without history of treatment with DPP-4 inhibitors and α-GIs or anti-hyperlipidemic drugs to evaluate the effect of anagliptin on lipid profile. Therefore, we could not include a sufficient number of patients. In addition, this study had an open-label design and the duration of anagliptin treatment was short. Therefore, a larger-scale, double-blinded study for a longer period of treatment is needed in the future.

In conclusion, anagliptin and miglitol are similarly effective on lipid and glycemic control.
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